Abstract
Previous research found that LIM domain kinase 2 (LIMK2) expression correlated with a poor prognosis in many cancers. However, its role in lung squamous cell carcinoma (LUSC) has not yet been clarified. Our study aimed to clarify the role of LIMK2 in LUSC prognosis prediction and explore the relationship between LIMK2 and immune infiltration in LUSC. In this study, we first analyzed the expression level and prognostic value of LIMK2 across cancers. Subsequently, we explored the association of LIMK2 expression with immune infiltrating cells and immune checkpoints. our study found that LIMK2 was highly expressed and positively associated with the overall survival of LUSC. Moreover, our study further indicated that LIMK2 expression was significantly negatively correlated with immune cell infiltration and immune checkpoints in LUSC. Finally, we confirmed upstream regulatory noncoding RNAs (ncRNAs) of LIMK2, and the PVT1 and DHRS4-AS1/miR-423-5p/LIMK2 regulatory axes were successfully constructed in LUSC. Put together, LIMK2 is a novel prognostic biomarker and correlates with tumor immune cell infiltration in LUSC, and the expression of LIMK2 is regulated by the PVT1 and DHRS4-AS1/miR-423-5p axes.
Highlights
Lung cancer (LC) is the second most frequent malignancy after breast cancer, and it is the principal cause of cancer-related mortality in the world [1]
non-small cell lung cancer (NSCLC) is one of the leading causes of cancer death [14], great progress has been made in treatment, especially in targeted therapy for lung adenocarcinoma (LUAD), which has greatly improved the prognosis of advanced LUAD
Based on the TIMER and GEPIA databases, this study found that LIM domain kinase 2 (LIMK2) was highly expressed in lung squamous cell carcinoma (LUSC)
Summary
Lung cancer (LC) is the second most frequent malignancy after breast cancer, and it is the principal cause of cancer-related mortality in the world [1]. Lung cancer can be divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC); lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) are two subtypes of NSCLC [2]. Different subtypes have different clinical characteristics, treatment methods, and prognoses. Mankind has made significant progress in diagnosis and treatment, the prognosis of lung cancer patients is still not optimistic, which causes at least 1.8 million deaths every year [1]. Finding new therapeutic targets and valuable prognostic markers are urgently needed.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
